Molecular target inhibitors have been regularly approved by Food and Drug Administration (FDA) for tumor treatment, and most of them intervene in tumor cell proliferation and metabolism. The RAS-RAF-MEK-ERK pathway is a conserved signaling pathway that plays vital roles in cell proliferation, survival, and differentiation. The aberrant activation of the RAS-RAF-MEK-ERK signaling pathway induces tumors. About 33% of tumors harbor RAS mutations, while 8% of tumors are driven by RAF mutations. Great efforts have been dedicated to targeting the signaling pathway for cancer treatment in the past decades. In this review, we summarized the development of inhibitors targeting the RAS-RAF-MEK-ERK pathway with an emphasis on those used in clinical treatment. Moreover, we discussed the potential combinations of inhibitors that target the RAS-RAF-MEK-ERK signaling pathway and other signaling pathways. The inhibitors targeting the RAS-RAF-MEK-ERK pathway have essentially modified the therapeutic strategy against various cancers and deserve more attention in the current cancer research and treatment.

Yanlin Song

Zhenfei Bi

Yu Liu

Furong Qin

Yuquan Wei

Xiawei Wei

Genes & Diseases

Genes & Diseases is an international journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

Aims and Scopes

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis will be placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Genes & Diseases is an international journal dedicated to molecular and translational medicine. The journal primarily publishes research on the molecular basis and experimental therapeutics of human diseases. Publication formats include full-length research articles, review articles, short communications, correspondence, perspectives, commentaries, views on news, and research watches.\n\nAims and Scope\n\nGenes & Diseases publishes rigorously peer-reviewed, high-quality original articles and authoritative reviews focusing on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to the pathogenesis and/or experimental therapeutics of human diseases. The journal features a global authorship and covers a broad range of basic and translational biomedical research in molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

《Genes and Diseases》是一本国际期刊，专注于分子和转化医学。该期刊主要发布关于人类疾病的分子基础和实验治疗的研究。出版格式包括完整的研究文章、综述文章、简短通讯、信函、观点、评论、新闻视角和研究动态。\n\n期刊目标与范围\n\n《Genes and Diseases》发表经过严格同行评审的高质量原创文章和权威综述，重点关注人类疾病的分子基础。特别强调与发病机制和/或人类疾病的实验治疗相关的假设驱动机制研究。该期刊拥有全球作者群，涵盖基础和转化生物医学研究的广泛领域，包括但不限于细胞增殖与凋亡、信号转导、干细胞生物学、发育生物学、基因调控与表观遗传学、癌症生物学、免疫与感染、神经科学、特定疾病动物模型、基因与细胞治疗以及再生医学。

Genes and Diseases

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials

The inhibitors targeting the RAS-RAF-MEK-ERK pathway have essentially modified the therapeutic strategy against various cancers and deserve more attention in the current cancer research and treatment.

Category	Quartile
医学	2
医学, 生化与分子生物学	2
医学, 遗传学	2

Targeting RAS–RAF–MEK–ERK signaling pathway in human cancer: Current status in clinical trials

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info

Category	Quartile
GENETICS & HEREDITY	1